Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2020 to Q4 2025

Type / Class
Equity / Common Stock, $0.0001 par value per share
Symbol
TARS on Nasdaq
Shares outstanding
42,194,093
Price per share
$81.88
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
44,887,391
Total reported value
$2,667,387,850
% of total 13F portfolios
0%
Share change
-1,300,132
Value change
-$49,410,129
Number of holders
217
Price from insider filings
$81.88
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RTW INVESTMENTS, LP 8.1% $134,159,372 3,424,180 RTW Investments, LP 30 Jun 2025
BlackRock, Inc. 7.4% $153,770,784 3,092,735 BlackRock, Inc. 31 Mar 2025
Deep Track Capital, LP 7.1% +25% $178,290,000 +$38,453,587 3,000,000 +27% Deep Track Capital, LP 30 Sep 2025
TANG CAPITAL MANAGEMENT LLC 5.9% $122,052,507 2,454,797 TANG CAPITAL MANAGEMENT, LLC 31 Mar 2025
MORGAN STANLEY 4.7% $96,628,483 1,943,453 Morgan Stanley 31 Mar 2025
Cowen Financial Products LLC 4.9% $94,926,816 1,909,228 Cowen Financial Products LLC 31 Dec 2024

As of 30 Sep 2025, 217 institutional investors reported holding 44,887,391 shares of Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS). This represents 106% of the company’s total 42,194,093 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) together control 85% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 9% 3,779,621 -0.33% 0% $224,622,876
RTW INVESTMENTS, LP 7.5% 3,177,436 +2.1% 2.3% $188,835,021
Deep Track Capital, LP 7.1% 3,000,000 +71% 5% $178,290,000
Paradigm Biocapital Advisors LP 6.3% 2,665,698 -10% 4.7% $158,422,432
JENNISON ASSOCIATES LLC 6.2% 2,604,580 +5.5% 0.09% $154,790,191
TANG CAPITAL MANAGEMENT LLC 5.8% 2,454,797 0% 5.6% $145,888,586
VANGUARD GROUP INC 5.4% 2,272,090 -1.1% 0% $135,030,309
MORGAN STANLEY 4.5% 1,912,402 -7% 0.01% $113,654,091
JANUS HENDERSON GROUP PLC 3.4% 1,438,999 -20% 0.04% $85,554,237
Assenagon Asset Management S.A. 3% 1,247,954 +25% 0.11% $74,165,906
Frazier Life Sciences Management, L.P. 2.8% 1,167,527 -16% 2.1% $69,386,130
Driehaus Capital Management LLC 2.4% 1,031,041 +18% 0.44% $61,274,767
LORD, ABBETT & CO. LLC 2.3% 985,629 -0.98% 0.17% $58,575,000
GEODE CAPITAL MANAGEMENT, LLC 2.2% 944,496 +1.1% 0% $56,140,457
Invesco Ltd. 2.2% 937,006 +0.92% 0.01% $55,686,267
STATE STREET CORP 2.2% 936,162 -4.6% 0% $55,636,108
MACQUARIE GROUP LTD 2% 833,437 -12% 0.06% $49,531,000
TORONTO DOMINION BANK 1.5% 617,583 -38% 0.07% $36,702,958
D. E. Shaw & Co., Inc. 1.4% 598,307 -17% 0.03% $35,557,385
Clearbridge Investments, LLC 1.3% 566,978 +28% 0.03% $33,695,506
Artisan Partners Limited Partnership 1.3% 558,326 +3.5% 0.05% $33,181,314
BANK OF AMERICA CORP /DE/ 1.3% 536,023 +15% 0% $31,855,847
Qube Research & Technologies Ltd 1.2% 522,276 +14% 0.04% $31,038,863
Ensign Peak Advisors, Inc 1.1% 482,364 -1% 0.05% $28,666,893
PRICE T ROWE ASSOCIATES INC /MD/ 1.1% 452,857 +18% 0% $26,914,000

Institutional Holders of Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 1,349,675 $110,367,215 -$29,974,190 $81.88 13
2025 Q3 44,887,391 $2,667,387,850 -$49,410,129 $59.43 217
2025 Q2 46,131,357 $1,868,819,935 +$92,954,236 $40.51 204
2025 Q1 43,564,795 $2,238,109,644 +$155,550,097 $51.37 191
2024 Q4 40,257,261 $2,228,992,305 -$65,425,283 $55.37 192
2024 Q3 43,391,345 $1,426,965,052 +$102,534,235 $32.89 161
2024 Q2 40,066,753 $1,089,006,566 +$6,596,629 $27.18 147
2024 Q1 39,323,641 $1,429,414,516 +$260,798,405 $36.35 155
2023 Q4 32,126,860 $650,570,328 +$49,625,202 $20.25 114
2023 Q3 29,793,106 $529,411,112 +$139,188,159 $17.77 105
2023 Q2 21,435,682 $387,312,097 +$39,178,138 $18.07 92
2023 Q1 20,057,814 $252,130,256 -$6,023,437 $12.57 73
2022 Q4 20,531,051 $300,987,054 +$5,059,618 $14.66 67
2022 Q3 20,489,091 $350,771,070 +$9,266,431 $17.12 72
2022 Q2 19,980,650 $291,715,823 +$98,791,820 $14.60 70
2022 Q1 13,210,299 $222,212,113 -$29,618,514 $16.82 50
2021 Q4 13,072,993 $294,217,317 +$4,316,413 $22.50 43
2021 Q3 12,869,541 $277,366,339 -$12,449,066 $21.55 43
2021 Q2 13,061,656 $378,528,053 +$8,240,890 $28.98 44
2021 Q1 12,761,893 $410,350,129 -$213,790 $32.23 41
2020 Q4 12,759,585 $523,637,183 +$523,637,191 $41.33 39